Agile Therapeutics - AGRX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $130.00
  • Forecasted Upside: 24,900.00 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.52
▼ -0.0218 (-4.02%)

This chart shows the closing price for AGRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Agile Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AGRX

Analyst Price Target is $130.00
▲ +24,900.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Agile Therapeutics in the last 3 months. The average price target is $130.00, with a high forecast of $160.00 and a low forecast of $100.00. The average price target represents a 24,900.00% upside from the last price of $0.52.

This chart shows the closing price for AGRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Agile Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/26/2022Maxim GroupUpgradeHold ➝ BuyLow
4/8/2022Maxim GroupDowngradeBuy ➝ HoldHigh
11/3/2021HC WainwrightLower TargetBuy$140.00 ➝ $100.00Medium
9/13/2021HC WainwrightLower TargetBuy$280.00 ➝ $140.00High
8/20/2021Maxim GroupReiterated RatingBuy$160.00Low
7/27/2021Royal Bank of CanadaReiterated RatingOutperform$240.00 ➝ $41.20Medium
5/5/2021OppenheimerReiterated RatingBuy$240.00High
12/8/2020HC WainwrightBoost TargetBuy$240.00 ➝ $280.00High
12/8/2020OppenheimerReiterated RatingBuy$400.00Medium
11/16/2020Royal Bank of CanadaReiterated RatingBuy$320.00Medium
11/13/2020OppenheimerReiterated RatingBuy$480.00Low
9/25/2020William BlairReiterated RatingBuyLow
9/9/2020Maxim GroupReiterated RatingBuy$320.00Low
8/12/2020HC WainwrightReiterated RatingBuyMedium
3/25/2020Royal Bank of CanadaReiterated RatingBuy$320.00Low
3/20/2020HC WainwrightLower TargetBuy$280.00 ➝ $240.00High
2/19/2020Janney Montgomery ScottBoost TargetBuy ➝ Fair Value$160.00 ➝ $360.00High
2/18/2020HC WainwrightBoost TargetBuy$200.00 ➝ $280.00Medium
2/18/2020Royal Bank of CanadaBoost TargetOutperform$200.00 ➝ $320.00Low
11/1/2019Maxim GroupReiterated RatingBuyHigh
10/31/2019William BlairUpgradeMarket Perform ➝ OutperformN/A
10/31/2019Royal Bank of CanadaBoost TargetOutperform$200.00Low
10/11/2019Maxim GroupSet TargetBuy$120.00Low
6/10/2019Maxim GroupSet TargetBuy$120.00Medium
6/6/2019OppenheimerInitiated CoverageOutperform$200.00 ➝ $200.00High
5/17/2019Maxim GroupSet TargetBuy$120.00Low
4/12/2019Janney Montgomery ScottInitiated CoverageBuy$160.00Low
2/11/2019Maxim GroupReiterated RatingBuy$120.00High
1/11/2019HC WainwrightReiterated RatingBuy$160.00Medium
11/29/2018Maxim GroupInitiated CoverageBuy ➝ Buy$120.00High
10/9/2018HC WainwrightSet TargetBuy$160.00High
5/21/2018Royal Bank of CanadaLower TargetOutperform$120.00High
5/21/2018HC WainwrightSet TargetBuy$160.00High
5/9/2018HC WainwrightSet TargetBuy$320.00Medium
3/14/2018Noble FinancialReiterated RatingBuyHigh
3/13/2018HC WainwrightReiterated RatingBuy$320.00High
12/28/2017HC WainwrightSet TargetBuy$320.00Low
12/28/2017Noble FinancialReiterated RatingBuyLow
12/28/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralLow
12/26/2017William BlairDowngradeOutperform ➝ Market PerformHigh
12/22/2017Noble FinancialReiterated RatingBuyHigh
12/22/2017Cantor FitzgeraldReiterated RatingBuy$200.00High
12/22/2017Janney Montgomery ScottDowngradeBuy ➝ NeutralHigh
12/22/2017HC WainwrightSet TargetBuy$320.00N/A
11/20/2017Cantor FitzgeraldReiterated RatingBuy$320.00N/A
11/6/2017Cantor FitzgeraldReiterated RatingBuy$320.00N/A
10/18/2017Royal Bank of CanadaReiterated RatingBuy$400.00N/A
10/12/2017HC WainwrightSet TargetBuy$400.00N/A
10/2/2017HC WainwrightReiterated RatingBuy ➝ Buy$400.00High
9/21/2017Cantor FitzgeraldReiterated RatingOverweight$320.00High
9/14/2017Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$320.00 ➝ $400.00High
9/7/2017Janney Montgomery ScottReiterated RatingBuy$520.00High
8/24/2017Janney Montgomery ScottReiterated RatingBuy$600.00 ➝ $520.00Low
(Data available from 8/18/2017 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/21/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/20/2022
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/20/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/19/2022
  • 5 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/19/2022
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/18/2022

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Agile Therapeutics logo
Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Agile Therapeutics, Inc. was incorporated in 1997 and is headquartered in Princeton, New Jersey.
Read More

Today's Range

Now: $0.52
Low: $0.52
High: $0.54

50 Day Range

MA: $0.82
Low: $0.50
High: $2.41

52 Week Range

Now: $0.52
Low: $0.49
High: $50.40

Volume

37,398 shs

Average Volume

5,739,211 shs

Market Capitalization

$2.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of Agile Therapeutics?

The following sell-side analysts have issued reports on Agile Therapeutics in the last twelve months: HC Wainwright, Maxim Group, and StockNews.com.
View the latest analyst ratings for AGRX.

What is the current price target for Agile Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Agile Therapeutics in the last year. Their average twelve-month price target is $130.00, suggesting a possible upside of 24,900.0%. Maxim Group has the highest price target set, predicting AGRX will reach $160.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $100.00 for Agile Therapeutics in the next year.
View the latest price targets for AGRX.

What is the current consensus analyst rating for Agile Therapeutics?

Agile Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AGRX will outperform the market and that investors should add to their positions of Agile Therapeutics.
View the latest ratings for AGRX.

What other companies compete with Agile Therapeutics?

How do I contact Agile Therapeutics' investor relations team?

Agile Therapeutics' physical mailing address is 101 POOR FARM ROAD, PRINCETON NJ, 08540. The specialty pharmaceutical company's listed phone number is (609) 683-1880 and its investor relations email address is [email protected] The official website for Agile Therapeutics is www.agiletherapeutics.com. Learn More about contacing Agile Therapeutics investor relations.